{"id":16955,"date":"2022-05-16T13:01:08","date_gmt":"2022-05-16T13:01:08","guid":{"rendered":"https:\/\/clinlabint.com\/?p=16955"},"modified":"2022-05-16T13:01:08","modified_gmt":"2022-05-16T13:01:08","slug":"thermo-fishers-new-customizable-cts-xenon-electroporation-system-enables-large-scale-cell-therapy-development-and-clinical-manufacturing","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/thermo-fishers-new-customizable-cts-xenon-electroporation-system-enables-large-scale-cell-therapy-development-and-clinical-manufacturing\/","title":{"rendered":"Thermo Fisher\u2019s new customizable CTS Xenon Electroporation System enables large-scale cell therapy development and clinical manufacturing"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Thermo Fisher\u2019s new customizable CTS Xenon Electroporation System enables large-scale cell therapy development and clinical manufacturing<\/h1>\/ in Product News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Thermo Fisher Scientific has introduced a new large-volume electroporation system that allows cell therapy developers to more easily move from clinical development to commercial manufacturing. The Gibco CTS Xenon Electroporation System leverages a closed, highly flexible design to facilitate gene modifications without the use of traditional viral vectors. The electroporation approach enables the introduction of a payload into a cell by temporarily increasing cell permeability using an electrical pulse.<\/p>\n

<\/p>\n

Unlike existing large-volume cell therapy electroporation solutions on the market,\u00a0the Gibco CTS Xenon Electroporation System features programmable, flexible electro-poration conditions, offering cell therapy developers full control to optimize a variety\u00a0of hard-to-transfect cell types and payloads. The system may be used as a standalone technology or integrated with the Gibco CTS Rotea Counterflow Centrifugation System as part of a modular, closed and automated cell therapy manufacturing workflow.<\/p>\n

\u201cWe launched the CTS Rotea System in 2020 as part of our strategy to deliver fit-for-purpose cell therapy solutions that can easily scale from development to commercialization. Adding the CTS Xenon Electroporation System to our end-to-end workflow will help customers overcome manufacturing challenges that hinder production, enabling them to bring life-saving therapies to patients faster,\u201d said Amy Butler, president of biosciences, Thermo Fisher Scientific.<\/p>\n

The CTS Xenon Electroporation System can transfect up to 2.5e9 cells in 25 mL in a sterile system, enabling rapid and efficient non-viral transfection for clinical manufacturing applications. In addition, it delivers up to 80% cell viability and 90% gene knockout transfection to seamlessly scale from the small-volume Neon Transfection System without the need for re-optimization of electroporation parameters.<\/p>\n

As a Cell Therapy Systems (CTS) solution, the Xenon Electroporation System is designed\u00a0to easily transition from the bench to the clinic. Thermo Fisher\u2019s CTS product line offers a comprehensive portfolio of GMP-manu-factured products backed by regulatory documentation and designed to work synergistically across the entire workflow, from cell isolation\/activation to cell engineering and expansion, to address cell therapy developers\u2019 manufacturing needs.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n
\n